Potential Drug-drug Interactions and Adverse Drug Reactions Associated with Hydroxychloroquine

Published on:January 2021
Indian Journal of Pharmacy Practice, 2021; 14(1):54-59
Original Article | doi:10.5530/ijopp.14.1.10


Potential Drug-drug Interactions and Adverse Drug Reactions Associated with Hydroxychloroquine


Authors and affiliation (s):

Arjun Singh1, Richa Chaudhary1, Prayas Verma2, Nilanchal Trivedi3,*, Md. Shamim4

1Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, Uttar Pradesh, INDIA.

2Teerthanker Mahaveer Dentaal College and Research Centre, TMU Moradabad, Uttar Pradesh, INDIA.

3Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, Uttar Pradesh, INDIA.

4LCP College of Pharmacy Baghpat, Abdul Kalam Technical University (AKTU), Uttar Pradesh, INDIA.

Abstract:

Introduction: COVID-19 is a pandemic disaster and a health emergency of prime focus for all the world economies. Various prophylactic treatments are considered to combat the disease. Hydroxychloroquine drug is one such option that is given much attention as an armor against SARS COV-2 pandemic. Evaluation and assessment of drug interactions and ADRs is required from ethical concern to justify the use of HCQ on such large scale. Methods: We have performed an analysis of HCQ drug interactions on Micromedex®. We have reviewed literature of HCQ pharmacokinetic properties, ADRs/ ADEs and toxicities associated with the use of HCQ drug on PubMed, Google Scholar and CDC database. Results: There are around 180 drug interactions possible with HCQ. Out of them 13 are of contraindicated severity level and other 165 are of major severity and 2 of them are moderately severe. Most of the interactions are coupled with QT prolonging agents (170), Cardiac arrhythmias is possible with the concomitant use of at least 2 drugs, 4 drugs leads to Torsade de points. System organ level ADRs are also evaluated along with various precautions, warnings and contraindications. Conclusion: Currently various options are available such as chloroquine, HCQ- azithromycin, remdesivir, plasma therapy and many others in the pipeline. Majority of patients are asymptomatic, therefore blind use of HCQ should be prohibited. Considering DDIs and ADRs associated with HCQ use, it should be used under clinical care with emphasizing proper screening in cardiovascular co-morbid patients.

Key words: Hydroxychloroquine, COVID-19, Drug Interactions, Adverse Drug Reactions, Micromedex®.




 

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmacy Practice (IJOPP) [ISSN-0974-8326] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 2008.

DOI HISTORY

IJOPP uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2014 are being assigned DOIs for its permanent URLs